Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

Lighthouse Pharmaceuticals receives a $49.2 million grant from the National Institute on Aging, aimed at advancing a Phase 2 ...

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

The collaboration will leverage Boehringer Ingelheim’s manufacturing expertise to accelerate AnGes’ HGF gene therapy toward ...

In a joint statement, 1 the White House and the EU announced the details of what is being called a framework for an agreement ...

Ken Banta, founder and CEO of The Vanguard Network, reveals the mindsets and moves biopharma leaders need to not just ...

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

Shiladitya Sengupta, founder, Vyome Therapeutics, explains how the company leveraged a reverse merger with ReShape ...

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

Rob Abbott, CEO, ISPOR, highlights how uniting regulators, payers, and academic leaders worldwide can accelerate access to ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...